Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Payables (2016 - 2025)

Cardiff Oncology's Payables history spans 15 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Payables rose 67.75% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $8.1 million, up 67.75%, while the annual FY2025 figure was $8.1 million, 67.75% up from the prior year.
  • Payables for Q4 2025 was $8.1 million at Cardiff Oncology, up from $2.4 million in the prior quarter.
  • Across five years, Payables topped out at $8.1 million in Q4 2025 and bottomed at $396000.0 in Q3 2021.
  • The 5-year median for Payables is $2.3 million (2023), against an average of $3.0 million.
  • The largest annual shift saw Payables tumbled 56.73% in 2021 before it soared 259.85% in 2022.
  • A 5-year view of Payables shows it stood at $1.4 million in 2021, then surged by 35.93% to $2.0 million in 2022, then increased by 0.51% to $2.0 million in 2023, then surged by 145.22% to $4.8 million in 2024, then surged by 67.75% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Payables are $8.1 million (Q4 2025), $2.4 million (Q3 2025), and $6.0 million (Q2 2025).